VRTX

434.30

1.01% -4.41

시장 영업 전: 432.01 -2.29 -0.53%

버텍스 파마슈티컬 (VRTX)

개요 뉴스 가격 이력 옵션 체인 Financials VRTX 왜 하락? 토론 예측 주식 분할

전일 마감가:

$438.71

열려 있는:

$437.79

하루 거래량:

948.69K

Relative Volume:

0.65

시가총액:

$110.47B

수익:

$12.07B

순이익/손실:

$3.95B

주가수익비율:

28.32

EPS:

15.3349

순현금흐름:

$3.19B

1주 성능:

-2.00%

1개월 성능:

-4.90%

6개월 성능:

+7.79%

1년 성능:

-8.50%

1일 변동 폭

$433.45

$440.90

1주일 범위

$433.45

$453.98

52주 변동 폭

$362.50

$510.77

버텍스 파마슈티컬 Stock (VRTX) Company Profile

명칭

Vertex Pharmaceuticals Inc

부문

Healthcare (1116)

산업

Biotechnology (624)

전화

(617) 341-6393

주소

50 NORTHERN AVENUE, BOSTON, MA

직원

6,400

트위터

@VertexPharma

다음 수익 날짜

2026-02-12

최신 SEC 제출 서류

VRTX's Discussions on Twitter

Compare VRTX vs REGN, ARGX, ALNY, INSM

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
VRTX Vertex Pharmaceuticals Inc	434.30	110.47B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.67B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.53B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	43.81B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.36B	606.42M	-1.28B	-997.58M	-6.403

버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-18	업그레이드	Maxim Group	Hold → Buy
2026-03-10	개시	Jefferies	Buy
2026-03-10	재확인	Oppenheimer	Outperform
2026-02-13	업그레이드	Oppenheimer	Perform → Outperform
2026-01-28	재개	Barclays	Overweight
2026-01-22	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2026-01-12	업그레이드	Bernstein	Mkt Perform → Outperform
2026-01-07	재개	UBS	Buy
2026-01-06	업그레이드	Wolfe Research	Peer Perform → Outperform
2025-12-03	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2025-11-13	개시	Scotiabank	Sector Outperform
2025-09-25	업그레이드	Leerink Partners	Market Perform → Outperform
2025-09-03	개시	Raymond James	Mkt Perform
2025-08-06	업그레이드	Wells Fargo	Equal Weight → Overweight
2025-05-07	다운그레이드	Wolfe Research	Outperform → Peer Perform
2025-05-06	다운그레이드	Leerink Partners	Outperform → Market Perform
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-02-12	업그레이드	Canaccord Genuity	Sell → Hold
2025-02-11	업그레이드	Canaccord Genuity	Sell → Hold
2025-01-30	다운그레이드	Wells Fargo	Overweight → Equal Weight
2024-12-20	재확인	H.C. Wainwright	Buy
2024-12-19	다운그레이드	Oppenheimer	Outperform → Perform
2024-12-09	업그레이드	Jefferies	Hold → Buy
2024-11-14	개시	Citigroup	Buy
2024-10-16	개시	Scotiabank	Sector Perform
2024-10-10	재개	Raymond James	Mkt Perform
2024-08-05	다운그레이드	Barclays	Overweight → Equal Weight
2024-06-27	개시	Redburn Atlantic	Buy
2024-04-11	업그레이드	Evercore ISI	In-line → Outperform
2024-02-15	개시	Wolfe Research	Outperform
2024-02-06	다운그레이드	Evercore ISI	Outperform → In-line
2024-02-02	다운그레이드	Bernstein	Outperform → Mkt Perform
2024-01-31	다운그레이드	Maxim Group	Buy → Hold
2024-01-31	다운그레이드	Robert W. Baird	Neutral → Underperform
2024-01-24	다운그레이드	Canaccord Genuity	Hold → Sell
2023-12-14	재확인	RBC Capital Mkts	Sector Perform
2023-05-30	개시	William Blair	Outperform
2023-05-04	재개	Piper Sandler	Overweight
2023-03-21	개시	Bernstein	Outperform
2023-01-18	개시	Canaccord Genuity	Hold
2023-01-17	업그레이드	SVB Leerink	Mkt Perform → Outperform
2022-12-19	다운그레이드	Jefferies	Buy → Hold
2022-07-13	개시	Cantor Fitzgerald	Overweight
2022-06-01	업그레이드	Maxim Group	Hold → Buy
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-05-06	다운그레이드	Robert W. Baird	Outperform → Neutral
2022-05-03	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2022-02-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-01-27	재확인	JP Morgan	Overweight
2022-01-27	재확인	Morgan Stanley	Underweight
2022-01-27	재확인	RBC Capital Mkts	Outperform
2022-01-27	재확인	Stifel	Hold
2022-01-27	재확인	Wolfe Research	Outperform
2022-01-20	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-12-09	개시	Wells Fargo	Overweight
2021-11-19	개시	BMO Capital Markets	Market Perform
2021-11-19	다운그레이드	Piper Sandler	Overweight → Neutral
2021-09-09	다운그레이드	Stifel	Buy → Hold
2021-09-07	다운그레이드	Morgan Stanley	Equal-Weight → Underweight
2021-07-20	다운그레이드	SVB Leerink	Mkt Perform → Underperform
2021-07-19	재개	Wolfe Research	Outperform
2021-07-01	개시	Raymond James	Mkt Perform
2021-06-11	다운그레이드	Daiwa Securities	Outperform → Neutral
2021-02-23	업그레이드	Robert W. Baird	Neutral → Outperform
2021-02-02	재확인	H.C. Wainwright	Buy
2020-12-30	개시	Daiwa Securities	Outperform
2020-11-30	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2020-11-20	개시	Bernstein	Outperform
2020-10-28	개시	UBS	Buy
2020-07-31	재확인	H.C. Wainwright	Buy
2020-07-08	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2020-04-30	재확인	H.C. Wainwright	Buy
2020-04-28	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2020-03-04	개시	Barclays	Overweight
2020-01-31	다운그레이드	Robert W. Baird	Outperform → Neutral
2019-11-19	업그레이드	Guggenheim	Neutral → Buy
2019-11-12	개시	SunTrust	Buy
2019-10-17	재개	BofA/Merrill	Buy
2019-09-03	업그레이드	Goldman	Neutral → Buy
2019-08-01	다운그레이드	Needham	Buy → Hold
2019-05-23	재개	Citigroup	Buy
2019-05-21	개시	Credit Suisse	Outperform
2019-04-12	개시	Evercore ISI	In-line
2019-03-26	업그레이드	William Blair	Mkt Perform → Outperform
2019-03-19	다운그레이드	SVB Leerink	Outperform → Mkt Perform
2019-02-06	다운그레이드	Maxim Group	Buy → Hold

모두보기

버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스

Apr 06, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 06, 2026

Vertex Pharmaceuticals Incorporated (VRTX) stock price, news, quote and history - Yahoo Finance UK

Apr 06, 2026

Vertex to Announce First Quarter 2026 Financial Results on May 4th - Business Wire

Apr 06, 2026

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.

Apr 06, 2026

Biotech layoff pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals

Apr 06, 2026

Apr 05, 2026

Best Biotech Stocks To Follow NowApril 5th - MarketBeat

Apr 05, 2026

Apr 04, 2026

CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 04, 2026

Apr 03, 2026

Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus

Apr 03, 2026

Vertex Pharmaceuticals EVP Sells $439,288 in Stock - National Today

Apr 03, 2026

Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $439,288.26 in Stock - MarketBeat

Apr 03, 2026

Vertex (VRTX) legal chief sells 978 shares under 10b5-1 plan - Stock Titan

Apr 03, 2026

Vertex Pharmaceuticals Inc (VX1.MU) Stock Forum & Discussion - Yahoo! Finance Canada

Apr 03, 2026

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup - ChartMill

Apr 03, 2026

Aberdeen Group Reduces Stake in Vertex Pharmaceuticals - National Today

Apr 03, 2026

Aberdeen Group plc Has $118.81 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Apr 03, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 03, 2026

Apr 02, 2026

Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Apr 02, 2026

[ARS] VERTEX PHARMACEUTICALS INC / MA SEC Filing - stocktitan.net

Apr 02, 2026

Vertex (NASDAQ: VRTX) posts $12B 2025 revenue and sets 2026 proxy votes - Stock Titan

Apr 02, 2026

Vertex Pharmaceuticals: Label Expansions For ALYFTREK & TRIKAFTA Plus Strong Demand (VRTX) - Seeking Alpha

Apr 02, 2026

Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - AOL.com

Apr 02, 2026

The Opioid Crisis Was an Innovation Failure. Vertex Just Showed a Way to Fix It - inc.com

Apr 02, 2026

F&V Capital Management LLC Buys Shares of 3,645 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Apr 02, 2026

Allspring Global Investments Holdings LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Apr 02, 2026

Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banque Pictet & Cie SA - MarketBeat

Apr 02, 2026

Apr 01, 2026

Vertex Advances FDA Filing for IgA Nephropathy Therapy - The Globe and Mail

Apr 01, 2026

Vertex Pharmaceuticals (VRTX) Submits Biologics Licensing Application for Accelerated FDA Approval - gurufocus.com

Apr 01, 2026

Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision - Yahoo Finance

Apr 01, 2026

Vertex Pharmaceuticals (NASDAQ: VRTX) reports 978-share Rule 144 resale and insider sales - Stock Titan

Apr 01, 2026

FDA Expands Vertex (VRTX) Drugs' Usage for Cystic Fibrosis - GuruFocus

Apr 01, 2026

Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval of Expanded Use of ALYFTREK (Vanzacaftor/Tezacaftor/Ivacaftor) - marketscreener.com

Apr 01, 2026

Vertex Pharmaceuticals IncFDA expands indication for trikafta in cf patients ages 2 and older - marketscreener.com

Apr 01, 2026

Vertex wins FDA label expansion for cystic fibrosis drugs - Seeking Alpha

Apr 01, 2026

, Expanding Availability of These Medicines to ~95% of All People With CF in the United States - Business Wire

Apr 01, 2026

Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune

Apr 01, 2026

Mar 31, 2026

Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators - Markets Mojo

Mar 31, 2026

Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus

Mar 31, 2026

Vertex (VRTX) CMO sells 2,329 shares in pre-set 10b5-1 trade - Stock Titan

Mar 31, 2026

Vertex Pharmaceuticals Incorporated Completes Submission of Biologics Licensing Application for Povetacicept to the U.S. Food and Drug Administration - marketscreener.com

Mar 31, 2026

[8-K] VERTEX PHARMACEUTICALS INC / MA Reports Material Event - Stock Titan

Mar 31, 2026

Promising Biotech Stocks To Watch NowMarch 31st - MarketBeat

Mar 31, 2026

Fierce Biotech Layoff Tracker 2026: Takeda plots 634 US job cuts - Fierce Biotech

Mar 31, 2026

Boston Common Asset Management LLC Sells 20,952 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Mar 31, 2026

Mar 30, 2026

Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - simplywall.st

Mar 30, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 30, 2026

VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 30, 2026

Vertex’s VX-407 Contraceptive Interaction Study Reaches Completion: What Investors Should Watch - TipRanks

Mar 30, 2026

BMO reiterates Vertex stock Outperform on cystic fibrosis strength By Investing.com - Investing.com UK

Mar 30, 2026

Mar 29, 2026

Best Biotech Stocks To Watch TodayMarch 29th - MarketBeat

Mar 29, 2026

Mar 28, 2026

Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta - TechStock²

Mar 28, 2026

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment - ChartMill

Mar 28, 2026